CRISPR Therapeutics Reports Q1 2026 Financial Results with CASGEVY Revenue of $43M and $2.44B Cash Position
CASGEVY generated $43.0M in revenue for Q1 2026 with over 500 patients initiated globally
Net loss was $122.9M for Q1 2026, improving from $136.0M in Q1 2025
Cash, cash equivalents, and marketable securities reached $2.44B as of March 31, 2026, up from $1.98B at year-end 2025
Company raised $585.4M in net proceeds from convertible senior notes issued in March 2026
R&D expenses were $68.6M and G&A expenses were $17.2M in Q1 2026, both lower than prior year
More than 60,000 eligible CASGEVY patients exist across approved countries
Multiple clinical milestones expected in H2 2026 including CTX460, CTX340 clinical starts, and in vivo liver editing program advances
Total revenue was $1.46M for Q1 2026 compared to $0.865M in Q1 2025